We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-8.87%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.94B
AUM Growth
-$1.55B
Cap. Flow
-$1.01B
Cap. Flow %
-34.35%
Top 10 Hldgs %
43.7%
Holding
135
New
15
Increased
7
Reduced
68
Closed
31

Top Buys

Rank Stock Value
1
GLUE icon
Monte Rosa Therapeutics
GLUE
+$65.1M
2
BMEA icon
Biomea Fusion
BMEA
+$56M
3
JBIO
Jade Biosciences
JBIO
+$46.4M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$46M
5
AMAM
Ambrx Biopharma Inc
AMAM
+$42.4M

Top Sells

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$76.5M
2
APLS
Apellis Pharmaceuticals
APLS
+$52.4M
3
NVAX icon
Novavax
NVAX
+$45.3M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$43.6M
5
OMER icon
Omeros
OMER
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 86.38%
2 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
51
Pharvaris
PHVS
$2.41B
$13.6M 0.46%
744,863
-119,280
-14% -$2.71M
CCCC icon
52
C4 Therapeutics
CCCC
$402M
$13.4M 0.46%
354,495
-2,135,570
-86% -$76.5M
BEAM icon
53
Beam Therapeutics
BEAM
$2.81B
$12.9M 0.44%
100,000
-71,775
-42% -$5.72M
CNTB
54
Connect Biopharma Holdings
CNTB
$138M
$12.7M 0.43%
650,000
-350,000
-35% -$5.84M
APTO
55
DELISTED
Aptose Biosciences, Inc.
APTO
$12.6M 0.43%
8,460
-429
-5% -$935K
GHRS icon
56
GH Research
GHRS
$2.1B
$12.6M 0.43%
+608,123
New +$12.4M
MYOV
57
DELISTED
Myovant Sciences Ltd.
MYOV
$12.4M 0.42%
542,499
-457,501
-46% -$9.63M
RPTX
58
DELISTED
Repare Therapeutics
RPTX
$11.3M 0.39%
363,766
-98,439
-21% -$3.22M
ELDN icon
59
Eledon Pharmaceuticals
ELDN
$267M
$11.2M 0.38%
1,415,500
– –
MORF
60
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$10.9M 0.37%
189,774
-160,226
-46% -$8.82M
HGEN
61
DELISTED
HUMANIGEN, INC.
HGEN
$10.4M 0.35%
600,000
-400,000
-40% -$7.29M
ANAB icon
62
AnaptysBio
ANAB
$1.62B
$9.98M 0.34%
385,081
-264,919
-41% -$6.35M
ASND icon
63
Ascendis Pharma A/S
ASND
$16.4B
$9.87M 0.34%
75,000
-25,000
-25% -$3.33M
ZLAB icon
64
Zai Lab
ZLAB
$2.36B
$9.46M 0.32%
53,455
-96,545
-64% -$15.5M
INSP icon
65
Inspire Medical Systems
INSP
$1.7B
$9.3M 0.32%
48,132
-36,868
-43% -$7.31M
TNGX icon
66
Tango Therapeutics
TNGX
$4.72B
$9.1M 0.31%
800,000
– –
DMRA
67
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$8.87M 0.3%
70,154
-15,875
-18% -$2.16M
TCRR
68
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$7.87M 0.27%
479,506
-420,494
-47% -$8.49M
HARP
69
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$7.5M 0.25%
54,060
-3,000
-5% -$572K
ATXS
70
DELISTED
Astria Therapeutics
ATXS
$7.49M 0.25%
+591,667
New +$7.68M
ITOS
71
DELISTED
iTeos Therapeutics
ITOS
$7.4M 0.25%
288,330
-11,670
-4% -$278K
SPRY icon
72
ARS Pharmaceuticals
SPRY
$551M
$7.39M 0.25%
239,099
-260,901
-52% -$8.37M
QURE icon
73
uniQure
QURE
$3.15B
$7.38M 0.25%
239,548
-10,452
-4% -$350K
INSM icon
74
Insmed
INSM
$28.7B
$7.12M 0.24%
250,000
-50,000
-17% -$1.48M
VERU icon
75
Veru
VERU
$37.1M
$6.46M 0.22%
80,000
-220,000
-73% -$19.4M
1 2
3
4 5

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Cormorant Asset Management held 135 positions worth $2.94B, down 34% from $4.49B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management withdrew a net $1.01B in Q2 2021, closing 31 positions and reducing 68 holdings. Its most notable exit was Novavax, an estimated $45.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 75% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Monte Rosa Therapeutics worth $69.5M.

  • Cormorant Asset Management's largest Q2 2021 buy was Monte Rosa Therapeutics: 3,193,973 shares worth $69.5M.
  • Cormorant Asset Management added most to Revolution Medicines in Q2 2021, an estimated $28.4M increase.
  • Cormorant Asset Management's biggest Q2 2021 reduction was C4 Therapeutics, cutting an estimated $76.5M.
  • Cormorant Asset Management fully exited Novavax in Q2 2021, selling an estimated $45.3M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2021.
  • Cormorant Asset Management opened 15 new positions and closed 31 in Q2 2021.
  • Cormorant Asset Management's portfolio value fell 34% quarter-over-quarter to $2.94B.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.